48Q Stock Overview A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
X4 Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for X4 Pharmaceuticals Historical stock prices Current Share Price US$0.58 52 Week High US$1.35 52 Week Low US$0.26 Beta 0.34 1 Month Change 67.05% 3 Month Change -6.79% 1 Year Change -13.23% 3 Year Change -72.52% 5 Year Change n/a Change since IPO -92.80%
Recent News & Updates
New major risk - Financial position Nov 16
New major risk - Share price stability Nov 14
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) Nov 13
X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Oct 24
New minor risk - Market cap size Oct 08
X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Aug 17 See more updates
New major risk - Financial position Nov 16
New major risk - Share price stability Nov 14
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) Nov 13
X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Oct 24
New minor risk - Market cap size Oct 08
X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Aug 17
X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 30
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index Jul 03
X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial Jun 27
New major risk - Financial position May 07 X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome Apr 30
X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 13
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 Dec 11 X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule Nov 15
X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome Nov 02
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors Oct 19
X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome Sep 06
Now 23% undervalued after recent price drop Aug 17
Director recently sold €125k worth of stock Aug 13
X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer Aug 10 X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding Aug 04
X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 03
X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome May 18
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia Dec 13 X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Dec 08
X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome Nov 30
X4 Pharmaceuticals, Inc. Announces Executive Changes Nov 04
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer Oct 27
X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN) Sep 28
X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022 Jul 30
X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones Jul 23 X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc. Jul 02
X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022 May 04
X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies Dec 15
X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia Dec 12 X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021 Jun 12
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract May 13
X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial May 07
New 90-day high: €8.30 Mar 11
Revenue beats expectations Mar 06
X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor Mar 05
X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021 Feb 12
New 90-day high: €7.30 Feb 10
New 90-day high: €6.15 Jan 10
X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer Dec 15
X4 Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of Whim Syndrome Dec 13
X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer Nov 03
New 90-day low: €5.00 Oct 29
X4 Pharmaceuticals, Inc. has Re-Assessed the Impacts of the Continuing COVID-19 Pandemic on the Ongoing Phase 1B Dose-Escalation Trial Oct 08
X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020 Oct 02
New 90-day low - €5.95 Sep 16
New 90-day low - €6.25 Jul 31
X4 Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 18
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Growth Index Jul 02 Shareholder Returns 48Q DE Biotechs DE Market 7D -6.7% -2.9% -2.6% 1Y -13.2% -14.7% 6.9%
See full shareholder returns
Return vs Market: 48Q underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 48Q's price volatile compared to industry and market? 48Q volatility 48Q Average Weekly Movement 18.1% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 48Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 48Q's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
Show more X4 Pharmaceuticals, Inc. Fundamentals Summary How do X4 Pharmaceuticals's earnings and revenue compare to its market cap? 48Q fundamental statistics Market cap €99.92m Earnings (TTM ) -€16.06m Revenue (TTM ) €1.08m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 48Q income statement (TTM ) Revenue US$1.12m Cost of Revenue US$495.00k Gross Profit US$628.00k Other Expenses US$17.39m Earnings -US$16.76m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.098 Gross Margin 55.92% Net Profit Margin -1,492.34% Debt/Equity Ratio 126.2%
How did 48Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 08:15 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Leah Rush Cann Brookline Capital Markets Arlinda Lee Canaccord Genuity Kristen Kluska Cantor Fitzgerald & Co.
Show 7 more analysts 
